Explore a complete
U.S. regulatory strategy.

United States Regulatory Strategy Fictional Catheter Introducer Sheath

FICTIONAL DEMONSTRATION REPORT

This fictional catheter introducer example demonstrates a regulatory pathway, an evidence plan and assigned next steps. It was prepared with a Panabistics candidate reporting workflow and does not represent the currently deployed release. Inputs are independently authored. No real-device testing, FDA clearance or regulatory sign-off is established. Actual submissions require current requirements, confirmed device details and verified supporting evidence.

Strategy purpose and scope

For CI-01 Independent Method Regression Sheath, retain the supplied device boundary and use Class II / 21 CFR 870.1340 / provisional DYB with Traditional 510(k) as the working U.S. planning position. Proposed sterilization method: Electron-beam irradiation. The evidence plan covers the actual dimensional/mechanical, use-related, biological, sterility and packaging/shelf-life questions. No additional kit component, coating, predicate, test result, validated process, exemption or FDA clearance is established. All software roles are explicitly absent; other technology applicability follows its own supplied presence fields. The output remains a partial profile-driven candidate assessment requiring final configuration, current-source, evidence and release review.

The case-specific conclusions, rationale, evidence requests, actions and questions below come from the same structured assessment object. The renderer does not expand the device boundary or add another case's analysis. The detailed plans define profile-specific work, outputs, owners, prerequisites and decision criteria. Evidence presence in an intake is not verification of supporting document contents.

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 1 of 102

Panabistics | U.S. Regulatory Strategy

Supplied device profile

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 2 of 102

Panabistics | U.S. Regulatory Strategy

Open questions

Does the final marketed device remain within the catheter-introducer definition and DYB scope? •

Required evidence

Final intended use and configuration mapped to the regulation and the current complete FDA • product-code record. [classification]

Recommended actions

Confirm product-code fit and document any exemption limitations after design inputs are • frozen. [high]

Classification decision record

The current working classification is bounded by the sheath function in 21 CFR 870.1340. DYB remains a product-code hypothesis requiring the complete current FDA record and the final marketed configuration. Product classification is distinct from a predicate choice, an exemption decision and a statement that the device has been cleared. A kit, added therapeutic function or materially different intended purpose may require a different analysis even when the word introducer remains in its name.

The classification record should capture the rule language considered, the profile facts supporting the match, alternatives screened out and the reviewer responsible for the decision. Unknown design attributes should be tracked where they could change the result. The engine rejects conflicting supplied class, regulation or product-code values in this bounded branch; that rejection is a request to reconcile the input, not an automated reassignment to a different class.

Regulation definition mapping

Planning record CLS-01. Show why the actual sheath function fits the working generic device definition.

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 9 of 102

Panabistics | U.S. Regulatory Strategy

Premarket pathway and decision sequence

Traditional 510(k) is the present planning baseline, subject to current product-code, exemption, sponsor-history and final-configuration review. This is a route to prepare and evaluate, not authorization to market. The plan should first establish the intended use and legally marketed comparator relationship, then determine whether the proposed evidence can answer the relevant safety and effectiveness questions. Unresolved differences may justify FDA interaction or a different route assessment.

eSTAR is the submission format when the applicable electronic-submission requirement applies. Completing template fields does not establish substantial equivalence or replace the supporting evidence. The program must separate administrative readiness, technical readiness and the eventual FDA decision. Submission timing and external expenditures should be based on an owned evidence plan; this strategy does not promise a clearance date or assign an unsupported testing budget.

Submission type and exemption assessment

Planning record PTH-01. Choose the submission route after reviewing the final device and the sponsor's actual regulatory history.

FDA interaction questions

Planning record PTH-02. Use focused regulatory questions when unresolved differences can change the evidence strategy.

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 12 of 102

Panabistics | U.S. Regulatory Strategy

Mechanical and simulated-use evidence addressing the final sheath and interface risks. [bench • and simulated use] Biological evaluation based on final patient-contacting materials, manufacturing residues and • contact duration. [biological safety] Electron-beam process validation and routine-control records tied to the final device and • packaging; evidence is requested, not assumed to exist. [sterility] Sterile-barrier, distribution, aging and shelf-life evidence supporting the actual package and • proposed expiry. [packaging and shelf life]

Recommended actions

Approve a traceable evidence plan before testing; retain missing evidence and unresolved • acceptance criteria as open items. [high]

Bench and simulated use evidence

The test program should answer defined design, risk and comparison questions. Protocols need the final device revision, representative test articles, conditioning, method suitability, sample-size rationale, acceptance criteria and deviation handling. A convenient sample set or a familiar test method is not automatically sufficient. Where materials, dimensions, compatibility or claims remain unknown, the program must first close the corresponding input before approving numerical limits and worst-case selection.

The evaluated boundary is Non-powered catheter introducer sheath and proximal hub only. No supplied catheter, needle, wire, dilator, valve, side port, or coating. Testing can address the interface with separately supplied equipment, but it must not transform that equipment into an included kit component. Potential mechanical injury, loss of integrity, incompatibility and contamination questions are planning concerns, not asserted failures of this fictional product. The plan should cover appropriate final-device, processing and aging conditions, with a written rationale for the coverage claimed.

Dimensional and configuration verification

Planning record TST-01. Verify that the final manufactured configurations meet approved design requirements and support the claimed interfaces.

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 45 of 102

Panabistics | U.S. Regulatory Strategy

Sterile barrier and packaging process

Planning record TST-09. Establish evidence that the final package can be reproducibly made and protect the sterile device through its intended life.

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 50 of 102

Panabistics | U.S. Regulatory Strategy

Visual labeling symbol glossary

The following actual symbol graphics are planning examples with adjacent explanations. Use the current applicable standard and final device evidence when releasing labeling. A method-specific graphic is shown only when the structured sterilization method is resolved.

Standard basis: ISO 15223-1 fourth edition 2021-07 including Amendment 1 2025, FDA recognition 5-148. The FDA record identifies December 17 2028 as the transition end for prior recognition 5-134.

Symbol	Meaning and reference	Application and decision
	Manufacturer ISO 15223-1 5.1.1 Identifies the manufacturer.	Place with the correct manufacturer identification where applicable; the report invents no address.
	Medical device ISO 15223-1 5.7.7 Identifies a medical device.	Use only for the controlled device and verified applicable labeling approach.
	Catalogue number ISO 15223-1 5.1.6 Identifies the catalogue or reference number.	Use the actual assigned identifier for the marketed model; no catalogue number is generated here.
	Batch code ISO 15223-1 5.1.5 Identifies the manufacturing batch or lot.	Link actual production information to release and traceability records; the report assigns no batch.
	Date of manufacture ISO 15223-1 5.1.3 Identifies the date of manufacture.	Use where appropriate with the actual controlled date; no date is assigned in this glossary.
	Do not reuse ISO 15223-1 5.4.2 Indicates that the device is intended for single use.	Match the controlled single-use statement and supporting risk/evidence decision.
	Consult instructions for use ISO 15223-1 5.4.3 Directs the user to the instructions for use.	Provide accessible controlled instructions for the actual intended users and device revision.

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 70 of 102

Panabistics | U.S. Regulatory Strategy

Symbol	Meaning and reference	Application and decision
	Caution ISO 15223-1 5.4.4 Directs attention to cautionary information.	Associate with relevant controlled warnings or precautions; the graphic alone does not communicate the full risk control.
	Do not use if package is damaged ISO 15223-1 5.2.8 Indicates not to use the device if its package is damaged and to consult the instructions.	Tie to the final sterile-barrier and package-inspection instructions and evidence.
	Unique device identifier ISO 15223-1 5.7.10 Identifies unique device identifier information.	Apply to actual assigned UDI information when applicable; the symbol does not assign or replace the identifier.
	Sterilized using irradiation ISO 15223-1 5.2.4 Indicates sterilization using irradiation.	Candidate method-matched symbol for the supplied electron-beam process; final use needs the approved sterile-state and process evidence.

Symbol artwork provenance

Artwork implementations from medical-device-symbols by Taig Mac Carthy. Source commit f83599e45613b269d4f85134bd1fd33ae2ef2a28. Converted from the pinned SVG files to black transparent PNGs with aspect ratio preserved. Each source and image hash is retained in the reviewed catalogue. The artwork is an implementation aid; its license does not determine device-specific regulatory applicability.

Artwork license source: https://github.com/t4dhg/medical-device-symbols/blob/f83599e45613b269d4f85134bd1fd33ae2ef2a28 /LICENSE

Manufacturer artwork: https://github.com/t4dhg/medical-device-symbols/blob/f83599e45613b269d4f85134bd1fd33ae2ef2a28 /src/icons/manufacturer.svg

Medical device artwork: https://github.com/t4dhg/medical-device-symbols/blob/f83599e45613b269d4f85134bd1fd33ae2ef2a28 /src/icons/md.svg

Catalogue number artwork: https://github.com/t4dhg/medical-device-symbols/blob/f83599e45613b269d4f85134bd1fd33ae2ef2a28 /src/icons/catalogue-number.svg

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 71 of 102

Panabistics | U.S. Regulatory Strategy

an evidence program matched to the actual finished-device risks. In this case the supplied sterile single-use and patient-contact facts require a real evidence strategy for biological evaluation, the selected sterilization process, package protection, use and functional performance. Software and cybersecurity exclusions remain restricted to their explicit factual bases.

The first priorities are the configuration/material/contact inputs and current regulatory-source decisions, followed by protocol and comparison planning. The later decisions concern evaluated evidence, claim and labeling release, submission authorization and operational readiness. The plan should be scheduled from actual prerequisites and resources; it provides no guaranteed clearance date, invented test budget or implied authorization to provision infrastructure. The following milestones separate decision readiness from completed evidence and external release.

Baseline and strategy decision milestone

Planning record EXE-01. Establish the facts and regulatory rationale needed before committing the main evidence program.

Evidence execution and reconciliation milestone

Planning record EXE-02. Make the resulting evidence useful for a coherent final regulatory argument.

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 89 of 102

Panabistics | U.S. Regulatory Strategy

Planning evidence and responsibility index

This index links each planning record to its evidence output, prerequisites and responsible function. The detailed record defines its work and acceptance basis. Evidence status in these records concerns verification by this assessment, and does not convert an intake availability declaration into a completed evidence review.

SAMPLE REPORT | Panabistics U.S. Regulatory Strategy | Page 92 of 102